Eton Pharmaceuticals and Aquestive Therapeutics announced a significant exclusive licensing deal for LIBERVANT® (diazepam) buccal film, aimed at improving treatment options for patients experiencing seizure clusters. This collaboration positions Eton to enter a U.S. market exceeding $450 million annually.
Expected Market Impact and Patient Preferences
According to recent market research, 71% of surveyed patients favored a buccal film over traditional nasal sprays, indicating a strong demand for alternatives in seizure management. This preference highlights the need for portable, user-friendly treatments.
LIBERVANT marks an important expansion of our portfolio into neurology and represents a compelling opportunity to bring an orphan-designated, differentiated therapy to patients.
Sean Brynjelsen, CEO of Eton Pharmaceuticals
- LIBERVANT is expected to launch in April 2027, pending FDA approval.
- The product has Orphan Drug Designation and patent protection until 2038.
Eton plans to leverage its existing commercial infrastructure to support the upcoming launch, building on its past successes with rare diseases. This includes establishing a dedicated neurology team and focusing on patient education and advocacy.
Regulatory Overview and Future Prospects
The FDA granted LIBERVANT Orphan Drug Designation in November 2016. The buccal film is currently under review, with a target action date for full approval set for March 29, 2027. This timeline aligns with the expiration of exclusivity for competing products, potentially expanding LIBERVANT's market reach.
As the healthcare landscape evolves, the collaboration between Eton and Aquestive represents a strategic move to address the unmet needs of epilepsy patients, particularly for those requiring quick, effective seizure rescue treatments.
About the Companies
Eton Pharmaceuticals specializes in developing and commercializing treatments for rare diseases, while Aquestive Therapeutics focuses on innovative delivery technologies. Together, they aim to enhance treatment options for patients with epilepsy.